Vaxart to Present at World Vaccine Congress Europe 2022 on October 13
October 10 2022 - 08:00AM
Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker,
Founder and Chief Scientific Officer, and Dr. James Cummings, Chief
Medical Officer, will make separate presentations at the World
Vaccine Congress Europe 2022 in Barcelona, Spain on Thursday,
October 13, 2022.
Presentation Information:
Title: Long-lasting nasal
mucosal responses in humans to SARS-CoV-2 following oral tablet
vaccine administration of non-replicating adenovirus expressing the
S and N proteinsSpeaker: Dr. Sean
TuckerDate: Thursday, October 13,
2022Time: 11:30 a.m. CET / 5:30 a.m. ET
Title: Potent immune responses
to norovirus G1.1 evaluated in elderly subjects following oral
tablet delivery. A phase 1 placebo-controlled
studySpeaker: Dr. James
CummingsDate: Thursday, October 13, 2022
Time: 12:00 p.m. CET / 6:00 a.m. ET
About VaxartVaxart is a
clinical-stage biotechnology company developing a range of oral
recombinant vaccines based on its proprietary delivery platform.
Vaxart vaccines are designed to be administered using tablets that
can be stored and shipped without refrigeration and eliminate the
risk of needle-stick injury. Vaxart believes that its proprietary
tablet vaccine delivery platform is suitable to deliver recombinant
vaccines, positioning the company to develop oral versions of
currently marketed vaccines and to design recombinant vaccines for
new indications. Vaxart’s development programs currently include
tablet vaccines designed to protect against coronavirus, norovirus,
seasonal influenza, and respiratory syncytial virus (RSV), as well
as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s
first immune-oncology indication. Vaxart has filed broad domestic
and international patent applications covering its proprietary
technology and creations for oral vaccination using adenovirus and
TLR3 agonists.
Contacts
Vaxart Media Relations: |
Investor Relations: |
Mark Herr |
Andrew Blazier |
Vaxart, Inc. |
FINN Partners |
mherr@vaxart.com |
IR@Vaxart.com |
(203) 517-8957 |
(646) 871-8486 |
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2023 to Mar 2024